United Therapeutics (UTHR) reported $3.2B in revenue for fiscal 2025, +10.6% year on year. That ranks #1062 by revenue among 2853 SEC filers and #94 in Healthcare. Net income was $1.3B, a net margin of 41.9%. Revenue has grown 10.9% a year on average since 2011 ($743M then). The fiscal 2025 balance sheet shows $7.9B in total assets and $1.6B in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.2B | +10.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $2.8B | +9.0% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $1.5B | +8.4% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.3B | +11.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.6B | +17.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $521M | +111.2% | FY20252025-12-31 |
| Total assetsAssets | $7.9B | +7.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $7.1B | +10.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $1.6B | −8.3% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $782M | $275M | Open → |
| Q2 20262026-06-30 | $783M | $333M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 1 of 161 companies compared | 41.9% | |
| Operating marginRank 3 of 160 companies compared | 46.9% | |
| R&D as share of revenueRank 32 of 102 companies compared | 17.3% | |
| Cash as share of revenueRank 7 of 160 companies compared | 48.9% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- United Therapeutics Corp
- Ticker
- UTHR
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001082554
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| BiontechBNTX | $3.2B | −$1.3B |
| Biomarin PharmaceuticalBMRN | $3.2B | $349M |
| Brookdale Senior LivingBKD | $3.2B | −$263M |
| United TherapeuticsUTHR | $3.2B | $1.3B |
| Minimed GroupMMED | $3.1B | −$333M |
| West Pharmaceutical ServicesWST | $3.1B | $494M |
| Amneal PharmaceuticalsAMRX | $3.0B | $72.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=United Therapeutics — Key figures |url=https://companiesranked.com/en/company/united-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). United Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/united-therapeuticsBibTeX
@misc{companiesranked-en-company-united-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{United Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/united-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001082554-26-000006 · February 25, 2026
{{cite web |title=United Therapeutics — Key figures — 10-K (0001082554-26-000006) |url=https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/uthr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.